New Drug-Delivery Methods: From Concept to Patient
11 October 2016
Increasing complexity is a trend in the bio/pharmaceutical industry. Both small- and large-molecule drug substances are becoming more complex and presenting both manufacturing and formulation challenges. Market pressures are also more complicated today than ever before. Expectations for lower-cost drugs that are easy to administer and offer significantly improved outcomes over existing treatments are growing.
CRISPR technology inactivates cancer mutations
11 October 2016
As for many other biomedical and biotechnology disciplines, the genome scissor “CRISPR / Cas9” opens up completely new possibilities for cancer research. Scientists have shown that mutations that act as cancer drivers can be targeted and repaired. The most relevant mutations could therefore be diagnosed faster, improving personalised therapies.
Lifestyle vs bad luck? New stem cell evidence provides insight to what causes cancer
10 October 2016
Researchers, funded by UK charity Worldwide Cancer Research, have found that the DNA code of human stem cells acquires errors at a fairly constant rate, even in organs with differing cancer incidence, providing new insight into the cancer bad luck vs lifestyle debate.
Pfizer offloads Hospira infusion therapy unit to ICU Medical for $1B
10 October 2016
Pfizer closed its $17 billion acquisition of Hospira just over a year ago, but is already offloading the infusion therapy business in a $1 billion deal. The deal will see ICU Medical picking up all of Hospira’s infusion offerings, including intravenous drugs and infusion pumps.
Brexit hits European life science M&A in Q3, as smaller deals set to become the norm
10 October 2016
In the first quarter after Britain voted to leave the European Union, life sciences deals took a nosedive--and while Asia booked impressive surges in M&A activity, the U.S. also saw a drop in deals as tax inversion rules and pricing pressures kick in.
Pfizer offloads Hospira infusion therapy unit to ICU Medical for $1B
07 October 2016
Pfizer closed its $17 billion acquisition of Hospira just over a year ago, but is already offloading the infusion therapy business in a $1 billion deal. The deal will see ICU Medical picking up all of Hospira’s infusion offerings, including intravenous drugs and infusion pumps.
Ethics in gene editing: U.K. taking deeper look at practical applications
07 October 2016
A U.K. enquiry into the moral and ethical issues raised by genome editing has concluded existing regulations provide sufficient oversight for the majority of applications but that its potential uses in treating inherited diseases by altering the germline in humans, and to increase production in livestock, requires urgent scrutiny.
Nobel Prize goes for autophagy research
07 October 2016
So said Yoshinori Ohsumi, honorary professor at the Tokyo Institute of Technology, after winning the 2012 Kyoto Prize in Life Sciences for his research.
06 October 2016
It’s time for drugmakers to stop relying so much on price increases to grow sales. That’s not a politician speaking; it’s influential Goldman Sachs analyst Jami Rubin, who analyzed pharma’s dependence on price hikes in a recent investor note.
Targeting cardiovascular disease risk factors may be important across a lifetime
06 October 2016
New findings suggest that all adults, including those over 65, should be mindful of risk factors for cardiovascular disease. The results, published in the Journal of the American Geriatric Society, are part of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, which looks at stroke incidence in approximately 30,000 individuals. The REGARDS study is funded by the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS).
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024